Spironolactone treatment was independently associated with a 10% lower risk of arterial stiffness (OR 0.90) and an 11% lower risk of composite cardiovascular disease in patients with increased arterial stiffness.
Cross-Sectional (n=444)
No
Does spironolactone treatment improve arterial stiffness and reduce composite cardiovascular disease in hypertensive patients?
In hypertensive patients, spironolactone use is associated with reduced arterial stiffness and a lower prevalence of composite cardiovascular disease specifically among those with increased arterial stiffness.
Effect estimate: OR 0.90 (95% CI 0.85-0.97)
Absolute Event Rate: 9.4% vs 10.1%
p-value: p=<0.05
Introduction: The aim of the current study was to evaluate the association of spironolactone and arterial stiffness and composite cardiovascular disease (CVD, including coronary heart disease, congestive heart failure and ischemic stroke) in hypertensive patients. Material and methods: Baseline data were collected and arterial stiffness was presented by carotid-femoral pulse wave velocity (cf-PWV) using applanation tonometry. Serum levels of fasting plasma glucose, total cholesterol, C-reactive protein and creatinine were measured using an automatic biochemistry analyzer. Plasma aldosterone concentration and plasma renin activity were determined by radioimmunoassay. The associations of spironolactone and arterial stiffness and composite CVD were evaluated. Results: = 170) were older and more likely to have diabetes and chronic heart failure. No differences in antihypertensive medications used were observed except for spironolactone. Mean number of antihypertensive medications used was significantly higher in the spironolactone group (2.6 ±0.8 vs. 2.2 ±0.6). Compared to patients without spironolactone, those with spironolactone had significantly lower cf-PWV (9.4 ±1.8 vs. 10.1 ±2.2 m/s). After adjustment for covariates, spironolactone was still associated with 10% lower risk of arterial stiffness, with a 95% confidence interval (CI) of 0.85-0.97. In patients without arterial stiffness, after adjustment for covariates, no significant association of spironolactone and composite CVD was observed. However, in patients with increased arterial stiffness, after adjustment for covariates, spironolactone was still independently associated with 11% lower risk of composite CVD (95% CI: 0.83-0.97). Conclusions: Spironolactone treatment is independently associated with lower cf-PWV and lower prevalence of composite CVD in patients with increased arterial stiffness.
Zeng et al. (Thu,) führten eine Querschnittsstudie bei Primärer Hypertonie (n=444) durch. Spironolacton vs. Keine Spironolacton-Behandlung wurde hinsichtlich der arteriellen Steifigkeit bewertet (OR 0,90, 95% CI 0,85-0,97, p=<0,05). Die Behandlung mit Spironolacton war unabhängig mit einem 10% niedrigeren Risiko für arterielle Steifigkeit (OR 0,90) und einem 11% niedrigeren Risiko für zusammengesetzte kardiovaskuläre Erkrankungen bei Patienten mit erhöhter arterieller Steifigkeit assoziiert.